T. Rowe Price Associates’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

T. Rowe Price Associates’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-17,373	Closed	-$205K	–	2654
2017 Q3	$205K	Buy	17,373 +6,900	+66%	+$77.4K	﹤0.01%	2407
2017 Q2	$110K	Hold	10,473	–	–	﹤0.01%	2473
2017 Q1	$115K	Hold	10,473	–	–	﹤0.01%	2475
2016 Q4	$142K	Hold	10,473	–	–	﹤0.01%	2434
2016 Q3	$129K	Buy	+10,473	New	+$123K	﹤0.01%	2413

Other funds holding SCMP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

T. Rowe Price Associates's SCMP Position: Q4 2017 in Review

T. Rowe Price Associates sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 17,373 shares — an estimated $205K sold.

T. Rowe Price Associates first reported a position in SCMP in Q3 2016 and held it in 5 quarters. The position peaked at $205K in Q3 2017. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

T. Rowe Price Associates reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
T. Rowe Price Associates sold 17,373 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $205K.
T. Rowe Price Associates first reported a position in Sucampo Pharmaceuticals, Inc. in Q3 2016 and held it in 5 quarters.
T. Rowe Price Associates's Sucampo Pharmaceuticals, Inc. position peaked at $205K in Q3 2017.
188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on T. Rowe Price Associates's 13F filing for Q4 2017, filed 14 Feb 2018.